Tenax Historical Financial Ratios

TENX Stock

USD 6.00 0.10 1.64%

Tenax Therapeutics is promptly reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 27.92, Invested Capital of 0.0, Average Payables of 375.4 K or Stock Based Compensation To Revenue of 0.0187 will help investors to properly organize and evaluate Tenax Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

About Tenax Financial Ratios Analysis

Tenax TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Tenax Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Tenax financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Tenax Therapeutics history.

Tenax Therapeutics Financial Ratios Chart

At this time, Tenax Therapeutics' Days Payables Outstanding is fairly stable compared to the past year. EV To Operating Cash Flow is likely to rise to 0.62 in 2025, whereas Days Sales Outstanding is likely to drop 166.06 in 2025.

Price To Sales Ratio Dividend Yield Days Sales Outstanding Average Payables

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Tenax Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Tenax Therapeutics sales, a figure that is much harder to manipulate than other Tenax Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Tenax Therapeutics dividend as a percentage of Tenax Therapeutics stock price. Tenax Therapeutics dividend yield is a measure of Tenax Therapeutics stock productivity, which can be interpreted as interest rate earned on an Tenax Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Most ratios from Tenax Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Days Payables Outstanding is fairly stable compared to the past year. EV To Operating Cash Flow is likely to rise to 0.62 in 2025, whereas Days Sales Outstanding is likely to drop 166.06 in 2025.

	2024	2025 (projected)
Dividend Yield	3.72	3.31
Price To Sales Ratio	134.5K	141.3K

Dividend Yield Price To Sales Ratio

Tenax Therapeutics fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality
Price To Sales Ratio		-0.19	0.46	0.61	0.17	-0.46	-0.06	0.03	-0.72	0.46	1.0	-0.05	-0.14	-0.2	0.13	0.13	0.26	0.84	0.13	0.48	-0.33	0.18	0.91	0.47	0.4	0.35
Dividend Yield	-0.19		-0.1	0.21	0.17	0.14	-0.2	0.6	0.08	-0.1	-0.19	-0.21	-0.1	-0.48	-0.28	0.0	0.08	-0.17	0.18	-0.27	-0.15	-0.8	-0.25	-0.27	-0.69	0.11
Ptb Ratio	0.46	-0.1		-0.32	0.17	-0.2	0.08	-0.18	-0.51	1.0	0.46	0.08	0.43	-0.66	0.28	0.53	0.12	0.31	0.11	0.35	-0.14	0.11	0.62	0.35	0.17	0.14
Days Sales Outstanding	0.61	0.21	-0.32		0.08	-0.27	-0.2	0.27	-0.38	-0.32	0.61	-0.19	-0.38	0.01	-0.19	-0.08	0.05	0.49	0.09	0.06	-0.26	-0.06	0.41	0.06	0.07	0.3
Book Value Per Share	0.17	0.17	0.17	0.08		-0.39	-0.71	0.29	0.22	0.17	0.17	-0.71	0.16	-0.17	-0.64	-0.03	0.11	0.25	0.98	0.27	-0.07	-0.17	0.23	0.27	-0.07	0.13
Free Cash Flow Yield	-0.46	0.14	-0.2	-0.27	-0.39		0.16	0.01	0.24	-0.2	-0.46	0.16	0.11	0.07	0.13	-0.07	-0.27	-0.39	-0.43	-0.52	0.05	-0.15	-0.48	-0.52	-0.22	-0.25
Operating Cash Flow Per Share	-0.06	-0.2	0.08	-0.2	-0.71	0.16		-0.03	-0.03	0.08	-0.06	1.0	-0.17	0.13	0.92	-0.09	0.24	0.06	-0.71	-0.09	0.07	0.21	-0.04	-0.09	0.19	-0.49
Average Payables	0.03	0.6	-0.18	0.27	0.29	0.01	-0.03		0.28	-0.18	0.03	-0.03	-0.57	0.11	0.03	-0.63	0.7	0.44	0.22	0.14	-0.11	-0.38	-0.08	0.14	-0.31	0.03
Capex To Depreciation	-0.72	0.08	-0.51	-0.38	0.22	0.24	-0.03	0.28		-0.51	-0.72	-0.04	0.01	0.46	-0.17	-0.47	-0.04	-0.39	0.24	-0.4	0.41	-0.07	-0.77	-0.4	-0.06	-0.43
Pb Ratio	0.46	-0.1	1.0	-0.32	0.17	-0.2	0.08	-0.18	-0.51		0.46	0.08	0.43	-0.66	0.28	0.53	0.12	0.31	0.11	0.35	-0.14	0.11	0.62	0.35	0.17	0.14
Ev To Sales	1.0	-0.19	0.46	0.61	0.17	-0.46	-0.06	0.03	-0.72	0.46		-0.05	-0.14	-0.2	0.13	0.13	0.26	0.84	0.13	0.48	-0.33	0.18	0.91	0.47	0.4	0.35
Free Cash Flow Per Share	-0.05	-0.21	0.08	-0.19	-0.71	0.16	1.0	-0.03	-0.04	0.08	-0.05		-0.17	0.13	0.93	-0.09	0.25	0.07	-0.71	-0.09	0.07	0.21	-0.03	-0.09	0.19	-0.49
Roic	-0.14	-0.1	0.43	-0.38	0.16	0.11	-0.17	-0.57	0.01	0.43	-0.14	-0.17		-0.56	-0.13	0.75	-0.68	-0.44	0.18	-0.34	0.47	0.1	0.02	-0.34	0.18	0.1
Inventory Turnover	-0.2	-0.48	-0.66	0.01	-0.17	0.07	0.13	0.11	0.46	-0.66	-0.2	0.13	-0.56		0.08	-0.81	0.26	0.11	-0.17	0.09	0.17	0.28	-0.36	0.09	0.25	-0.21
Net Income Per Share	0.13	-0.28	0.28	-0.19	-0.64	0.13	0.92	0.03	-0.17	0.28	0.13	0.93	-0.13	0.08		-0.09	0.39	0.29	-0.7	0.06	0.14	0.28	0.18	0.06	0.31	-0.23
Days Of Inventory On Hand	0.13	0.0	0.53	-0.08	-0.03	-0.07	-0.09	-0.63	-0.47	0.53	0.13	-0.09	0.75	-0.81	-0.09		-0.63	-0.33	0.01	-0.17	-0.03	0.15	0.32	-0.18	0.05	0.14
Payables Turnover	0.26	0.08	0.12	0.05	0.11	-0.27	0.24	0.7	-0.04	0.12	0.26	0.25	-0.68	0.26	0.39	-0.63		0.68	0.01	0.55	-0.22	-0.08	0.25	0.54	-0.11	0.1
Capex To Revenue	0.84	-0.17	0.31	0.49	0.25	-0.39	0.06	0.44	-0.39	0.31	0.84	0.07	-0.44	0.11	0.29	-0.33	0.68		0.15	0.6	-0.28	0.16	0.75	0.59	0.36	0.22
Cash Per Share	0.13	0.18	0.11	0.09	0.98	-0.43	-0.71	0.22	0.24	0.11	0.13	-0.71	0.18	-0.17	-0.7	0.01	0.01	0.15		0.24	-0.07	-0.19	0.17	0.24	-0.09	0.07
Pocfratio	0.48	-0.27	0.35	0.06	0.27	-0.52	-0.09	0.14	-0.4	0.35	0.48	-0.09	-0.34	0.09	0.06	-0.17	0.55	0.6	0.24		-0.33	0.27	0.61	1.0	0.28	0.23
Interest Coverage	-0.33	-0.15	-0.14	-0.26	-0.07	0.05	0.07	-0.11	0.41	-0.14	-0.33	0.07	0.47	0.17	0.14	-0.03	-0.22	-0.28	-0.07	-0.33		0.15	-0.33	-0.33	0.23	0.13
Payout Ratio	0.18	-0.8	0.11	-0.06	-0.17	-0.15	0.21	-0.38	-0.07	0.11	0.18	0.21	0.1	0.28	0.28	0.15	-0.08	0.16	-0.19	0.27	0.15		0.25	0.27	0.68	-0.05
Capex To Operating Cash Flow	0.91	-0.25	0.62	0.41	0.23	-0.48	-0.04	-0.08	-0.77	0.62	0.91	-0.03	0.02	-0.36	0.18	0.32	0.25	0.75	0.17	0.61	-0.33	0.25		0.6	0.38	0.31
Pfcf Ratio	0.47	-0.27	0.35	0.06	0.27	-0.52	-0.09	0.14	-0.4	0.35	0.47	-0.09	-0.34	0.09	0.06	-0.18	0.54	0.59	0.24	1.0	-0.33	0.27	0.6		0.28	0.23
Days Payables Outstanding	0.4	-0.69	0.17	0.07	-0.07	-0.22	0.19	-0.31	-0.06	0.17	0.4	0.19	0.18	0.25	0.31	0.05	-0.11	0.36	-0.09	0.28	0.23	0.68	0.38	0.28		-0.02
Income Quality	0.35	0.11	0.14	0.3	0.13	-0.25	-0.49	0.03	-0.43	0.14	0.35	-0.49	0.1	-0.21	-0.23	0.14	0.1	0.22	0.07	0.23	0.13	-0.05	0.31	0.23	-0.02

Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	4.17	5.04	2.19	0.67	0.61	0.64
Book Value Per Share	714.04	330.07	81.17	32.65	29.39	27.92
Free Cash Flow Yield	(0.48)	(0.51)	(3.68)	(1.08)	(1.25)	(1.18)
Operating Cash Flow Per Share	(1.4K)	(844.18)	(653.19)	(23.8)	(21.42)	(22.5)
Capex To Depreciation	0.0304	0.0482	0.0205	0.38	0.43	0.41
Pb Ratio	4.17	5.04	2.19	0.67	0.61	0.64
Free Cash Flow Per Share	(1.4K)	(844.59)	(653.32)	(23.8)	(21.42)	(22.5)
Roic	(2.01)	(7.27)	(4.8)	(0.96)	(1.1)	(1.16)
Net Income Per Share	(1.5K)	(2.5K)	(600.46)	(31.09)	(27.98)	(29.38)
Payables Turnover	0.15	0.13	0.25	0.003651	0.003286	0.003451
Cash Per Share	1.0K	434.21	115.47	39.48	35.54	33.76
Pocfratio	(2.08)	(1.97)	(0.27)	(0.92)	(0.83)	(0.87)
Capex To Operating Cash Flow	(3.76E-4)	(4.84E-4)	(1.93E-4)	(4.82E-4)	(4.33E-4)	(4.55E-4)
Pfcf Ratio	(2.08)	(1.97)	(0.27)	(0.92)	(0.83)	(0.87)
Days Payables Outstanding	2.4K	2.9K	1.4K	100.0K	90.0K	94.5K
Income Quality	0.39	0.9	0.94	0.33	1.09	0.77
Roe	(2.13)	(7.71)	(7.4)	(0.95)	(1.09)	(1.04)
Ev To Operating Cash Flow	(1.44)	(1.48)	(0.16)	0.65	0.59	0.62
Pe Ratio	(1.95)	(0.65)	(0.3)	(0.71)	(0.64)	(0.67)
Return On Tangible Assets	(1.44)	(5.46)	(3.24)	(0.66)	(0.59)	(0.62)
Ev To Free Cash Flow	(1.44)	(1.48)	(0.16)	0.65	0.59	0.62
Earnings Yield	(0.51)	(1.53)	(3.38)	(1.42)	(1.63)	(1.55)
Net Debt To E B I T D A	0.61	0.16	0.12	1.13	1.02	1.07
Current Ratio	3.21	3.64	1.74	3.26	3.75	6.17
Tangible Book Value Per Share	714.04	330.07	81.17	32.65	29.39	27.92
Graham Number	4.9K	4.3K	1.0K	151.14	173.81	165.12
Shareholders Equity Per Share	714.04	330.07	81.17	32.65	29.39	27.92

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Tenax Historical Financial Ratios

About Tenax Financial Ratios Analysis

Tenax Therapeutics Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Average Payables

Tenax Therapeutics fundamentals Correlations

Tenax Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tenax Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Tenax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Cash Per Share	+ 0.98	Book Value Per Share
Net Income Per Share	+ 0.93	Free Cash Flow Per Share

Days Of Inventory On Hand	- 0.81	Inventory Turnover
Payout Ratio	- 0.8	Dividend Yield
Capex To Operating Cash Flow	- 0.77	Capex To Depreciation
Ev To Sales	- 0.72	Capex To Depreciation
Capex To Depreciation	- 0.72	Price To Sales Ratio
Cash Per Share	- 0.71	Free Cash Flow Per Share